However, changes from squamous PDAC toward a less aggressive (classical) disease phenotype might only be achieved when a tumor shifts from a major KRAS imbalance that disappears after therapy, due to subsequent outgrowth of minor clone(s) that carry no KRAS imbalance [136]. The gene discussed is KRAS; the disease is neoplasm.